Experienced Hematologist and Medical Oncologist Harminder Sethi, MD joins

Maryland Oncology Hematology

Dr. Sethi has over 18 years of experience, specializing in targeted and biological therapy.

Hyattsville, MD March 29, 2022 --(PR.com)-- Maryland Oncology Hematology (MOH), the largest
independent oncology practice in Maryland and a member of The US Oncology Network, has added
Harminder Sethi, MD, to their hematology and medical oncology team. Dr. Sethi specializes in treatment
plans that include targeted and biological therapy designed to treat the unique intricacies of each patient’s
illness. “Dr. Sethi will see patients at the Hyattsville office located at 6505 Belcrest Rd., Hyattsville, MD
20782, as well as the White Oak Cancer Center at 11886 Healing Way Suite 701, Silver Spring, MD,
20904 once a week. Upon its opening, he will also see patients at the DC office located at 1140 Vamum
St. NE in Washington, DC.

Dr. Sethi completed his initial medical education in India before finishing his residency at North Shore
University Hospital, NY followed by fellowship in oncology/hematology at Medstar Washington
Hospital Center. During his fellowship, Dr. Sethi completed bone marrow transplant training in affiliation
with the Fred Hutchinson Cancer Center in Seattle, WA and additional oncology training with the
National Heart, Blood and Lung Institute. Dr. Sethi has an ardent respect for his patients and develops
treatment plans that include targeted therapy and biological therapy based on the most up-to-date national
guidelines tailored to each patient’s particular circumstances and goals.

“I’m thrilled to join the team at Maryland Oncology Hematology to serve patients throughout our
community,” said Dr. Sethi, hematology and medical oncologist, MOH. “Through our access to the latest
technology and groundbreaking treatments, I’m happy to bring patients new hope in fighting cancer.”

“Dr. Sethi is an excellent addition to MOH,” said Joseph Haggerty, MOH Practice President. “His
impressive experience in both hematology and medical oncology will provide a great benefit to the local
community.”

To learn more or to schedule an appointment, visit MarylandOncology.com or call 301.343.3892.

About Maryland Oncology Hematology

Maryland Oncology Hematology (MOH) is the largest independent oncology practice in the state of
Maryland, with more than 45 practicing clinicians devoted exclusively to providing comprehensive,
compassionate, and high-quality cancer care. MOH specializes in medical, gynecologic, hematology,
cancer genetic risk assessment, clinical trials and research, and patient ancillary programs. MOH believes
it is beneficial to provide cancer therapies in a community setting, close to patients’ homes and support
systems. The physicians are supported by a talented clinical team sensitive to the needs of cancer patients
and their caregivers. For more information, visit MarylandOncology.com.

About US Oncology Network

Page 1 of 4
PR.com Press Release Distribution Terms
Maryland Oncology Hematology is a practice in The US Oncology Network (The Network). This
collaboration unites the practice with more than 1,400 independent physicians dedicated to delivering
value-based, integrated care to patients — close to home. Through The Network, these independent
doctors come together to form a community of shared expertise and resources dedicated to advancing
local cancer care and to delivering better patient outcomes. The Network is supported by McKesson
Corporation, whose coordinated resources and infrastructure allow doctors in The Network to focus on
the health of their patients, while McKesson focuses on the health of their practices. Maryland Oncology
Hematology also participates in clinical trials through US Oncology Research, which has played a role in
more than 100 FDA-approved cancer therapies.

Page 2 of 4
PR.com Press Release Distribution Terms
Contact Information:
Maryland Oncology Hematology
Mark W. Lamplugh Jr.
561-7629-729
Contact via Email
marylandoncology.com

Online Version of Press Release:

https://www.pr.com/press-release/858087

Page 3 of 4
PR.com Press Release Distribution Terms
 Page 4 of 4
PR.com Press Release Distribution Terms